Researchers' interest in the last few years has been concentrated on finding a medical, if possible, or at least “mini-invasive” therapy for benign prostatic hypertrophy (BPH), which can be used for the symptomatic form instead of open or endoscopic surgery. The various therapeutic options are reviewed, underlining their advantages and disadvantages.
FitzpatrickJ.M., DreikornK., KhouryS., KovanaiT., PerrinP.: The medical management of BPH with agents other than hormones or alpha-blockers. The International Consultation on Benign Prostatic Hyperplasia (BPH). Paris, 195–199, 1991.
2.
GellerJ.: Pathogenesis and medical treatment of benign prostatic hyperplasia. Prostate, suppl.2: 95–104, 1989.
3.
PeirsonE.L.: A study of the effects of stilbestrol therapy on the size of the benign hypertrophied prostate gland. J. Urol., 55: 73, 1943.
4.
PaulsonD.F., KaneR.D.: A prospective study in the pharmaceutical management of benign prostatic hypertrophy. J. Urol., 113: 811, 1985.
5.
Mc ConnelJ.D.: Androgen ablation and blockade in the teatment of benign prostatic hyperplasia. Urol. Clin. North Am., 17: 661–670, 1990.
6.
SchweikertH.U., TunnU.W.: Effects of the aromatase inhibitor testolactone on human benign hyperplasia. Steroids, 50: 191–200, 1987.
7.
TunnU.V., KaiversP., ScheweikertU.: Conservative treatment of human benign prostatic hyperplasia, in: BruchovskyN., ChapdelaineA., NeumannF. (eds): Regulation of androgen action, proceedings of an international symposium. Montreal 1984, Berlin R. Bruckner, pp. 87–92, 1985.
8.
HendersonD., HabenichtU.F., NishinoY., KerbU., El EtrebyM.F.: Aromatase inhibitors and benign prostatic hyperplasia. J. Steroid. Biochem., 25: 867, 1986.
9.
CaineM.: The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J. Urol., 136: 14, 1986.
10.
LeporH.: Alpha-1-adrenergic blockers in the medical management of benign prostatic hypertrophy. Curr. Op. Urol.2, 26–29, 1992.
11.
FowlerF.G., WennbergJ.E., TimothyR.P., BarryM.J., MulleyA.G.Jr., HanleyD.: Symptom status and quality of life following prostatectomy. Jama, 259: 3019–22, 1988.
12.
WennbergJ.E., RoosS., SolaR.: Use of claims data system to evaluate health care outcomes: mortality and reoperation following prostatectomy. Jama, 257: 933–6, 1987.
13.
AnselmoG., MaccatrozzoL., TuccittoG.: Ruolo della chirurgia aperta. Urologia, 59(1): 38–44, 1992.
14.
OrandiA.: Transurethral resection vs transurethral incision of the prostate. Urol. Clin. North Am., 17: 601–612, 1990.
15.
Turner-WarwickR., WhitesideC.G., WorthP.H.L., MilroyE.J.G., BatesC.P.: A urodynamic view of the clinical problems associated with bladder neck dysfunction and its treatment by endoscopic incision and transtrigonal posterior prostatectomy. Br. J. Urol., 45: 44–49, 1973.
16.
Mc CulloghgG., Winston-SalemN.C., RothR.A., BurlingtonM.A., BabaianR.K. and Cooperative Group: Tulip-Transurethral ultrasound guided laser induced prostatectomy. National human cooperative study results. Aua 1992, abs 375. J. Urol., 167: 3064, 1992.
17.
CostelloA.J., BoltonD.M., BowsherW.G.: Laser ablation of the prostate in patients with benign prostatic hypertrophy. Aua1992, abs 376.
18.
SchulmanC.C., ZlottaA.R., RasorJ.S.: Transurethral needle ablation (TUNA): safety, feasibility and tolerance of a new office procedure for treatment- of benign prostatic hyperplasia. Eur. Urol., 24(3): 415–423, 1993.
19.
KleinL.A.: Balloon dilatation of the prostate as compared with transurethral resection of the prostate for treatment of benign prostatic hypertrophy. World. J. Urol., 9: 29–31, 1991.
20.
DeistingW.: Transurethral dilatation of the prostate. A new method in the treatment of prostatic hypertrophy. Urol. Int., 2: 158–171, 1956.
